Clinical Trial

STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation

Name: STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation — clinical trial record (NCT07754734)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To compare the efficacy and safety of Lenvatinib combined with the standard Stupp regimen versus the standard Stupp regimen alone in the treatment of newly diagnosed glioblastoma with MGMT promoter methylation positive.

Trial Details

NCT Number	NCT07754734
Lead Sponsor	Dongguan People's Hospital
Conditions	Glioma, Glioblastoma (GBM), MGMT-Methylated Glioblastoma
Enrollment	138 participants
Start Date	2026-08-10
Primary Completion	2029-07-31 (estimated)
Study Completion	2029-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-10